Zura Bio Highlights Dual-Pathway Antibody Tibulizumab at Upcoming EULAR 2024 Conference

6/3/24 6:06:48 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $ZURA alert in real time by email

Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced it will present data from its tibulizumab (ZB-106) program exploring the clinical potential of the dual-pathway antibody in Sjogren's syndrome and rheumatoid arthritis (RA) at EULAR 2024, June 12-15 in Vienna.

Get the next $ZURA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ZURA

Date	Price Target	Rating	Analyst
11/4/2024	$15.00	Outperform	Leerink Partners
9/5/2024	$5.00	Neutral	H.C. Wainwright
5/3/2024	$26.00	Overweight	Piper Sandler
10/10/2023	$10.00	Buy	Ladenburg Thalmann
8/25/2023	$17.00	Outperform	Oppenheimer
6/22/2023	$20.00	Buy	Guggenheim
6/14/2023	$14.00	Buy	Chardan Capital Markets
5/24/2023	$20.00	Strong Buy	Raymond James

More analyst ratings

Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis
Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the submission of a protocol to its open Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a Phase 2 study evaluating tibulizumab, a humanized tetravalent bispecific dual antagonist antibody designed to neutralize both IL-17A and BAFF, for the treatment of systemic sclerosis (SSc) in adults. "Systemic sclerosis presents significant unmet needs, as current treatments largely target only its interstitial lung disease (ILD) component," said Robert Lisicki,
11/14/24 4:30:00 PM ET
$ZURA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
Expect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in Q4 2024 and hidradenitis suppurativa (HS) in Q2 2025 Cash, cash equivalents and investments totaling $188.2 million as of September 30, 2024, are anticipated to support operations, as currently planned, through 2027 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported financial results for the third quarter of 2024 and recent corporate updates. "In the third quarter of 2024, we made significant progress toward initiating our first Phase 2 tria
11/7/24 6:30:00 AM ET
$ZURA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Zura Bio to Participate in Two Upcoming Investor Conferences in November
Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in two investor conferences in November. Conference Details: Event: Guggenheim Inaugural Healthcare Innovation Conference Details: Participating in a fireside chat on Tuesday, November 12, 2024, at 1:00 p.m. ET and hosting investor meetings in Boston, MA. Event: Jefferies London Healthcare Conference Details: Hosting investor meetings Thursday, November 21, 2024, in London, UK. Links for live webcasts and replays, if available, will be po
10/30/24 6:30:00 AM ET
$ZURA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Presented data for tibulizumab at EULAR 2024, highlighting the potential relevance of dual-inhibition of both IL-17A and BAFF in autoimmune and inflammatory diseases Expect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in 4Q 2024 and hidradenitis suppurativa (HS) in 2Q 2025 Strengthened management and advisory team with appointment of Robert Lisicki as CEO & formation of Scientific Advisory Board Cash, cash equivalents and investments of $188.4 million as of June 30, 2024, including $112.5 million from private placement executed in April 2024, anticipated to support operations as currently planned through 2027 Zura Bio Limited
8/13/24 9:21:00 AM ET
$ZURA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer
Significant 2023 milestones highlighted by successful Nasdaq listing, leadership team buildout, formation of strategic development and scientific plan On track to initiate Phase 2 study evaluating tibulizumab (ZB-106) for the treatment of systemic sclerosis (SSc) in 2H 2024 Appointment of CEO, Robert Lisicki, underscores Zura Bio's commitment to building leading immunology company as we prioritize excellence in strategic development and scientific planning Outgoing Founder and CEO, Someit Sidhu, M.D., will continue as a Board Director to leverage institutional knowledge and provide continued support Cash position as of December 31, 2023 totaling $99.8 million in cash, cash equi
3/28/24 6:00:00 AM ET
$ZURA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO
Accomplished biopharmaceutical executives bring invaluable expertise and experience to Zura Bio's Clinical Development programs Executive Leadership hires position Zura Bio for Phase 2 clinical trial readiness across multiple indications in 2024 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the appointments of Robert Lisicki as President and Chief Operating Officer, and Kiran Nistala, MBBS, PhD, as Executive Vice President Development and Chief Medical Officer, to the Executive Leadership Team. Mr. Lisicki will be responsible for developing an
1/8/24 6:00:00 AM ET
$ZURA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$ZURA
Financials

Live finance-specific insights

Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
Expect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in Q4 2024 and hidradenitis suppurativa (HS) in Q2 2025 Cash, cash equivalents and investments totaling $188.2 million as of September 30, 2024, are anticipated to support operations, as currently planned, through 2027 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported financial results for the third quarter of 2024 and recent corporate updates. "In the third quarter of 2024, we made significant progress toward initiating our first Phase 2 tria
11/7/24 6:30:00 AM ET
$ZURA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights
Initiating Phase 2 clinical trials in 2024 to evaluate ZB-106 (tibulizumab) in systemic sclerosis and hidradenitis suppurativa, and ZB-168 in alopecia areata Experienced team building the next Immunology leader Cash position of $103.9 million in cash, cash equivalents and investments is expected to support development and operations into 2026 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio") a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced its financial results for the quarter ended September 30, 2023, and recent business highlights. "In the third quarter, Zura Bio made significant progress
11/13/23 6:30:00 AM ET
$ZURA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Zura Bio Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Focused on advancing ZB-106, a potential first-in-class anti-IL-17 and anti-BAFF dual antagonist for systemic sclerosis and hidradenitis suppurativa Experienced team building the next immunology leader Cash and cash equivalents of $113 million support development and operations through 2026 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced its financial results for the second quarter ended June 30, 2023, and recent business highlights. "Zura Bio made great progress in the first half of 2023, and we look forward to advancing
8/14/23 7:00:00 AM ET
$ZURA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Zura Bio Highlights Dual-Pathway Antibody Tibulizumab at Upcoming EULAR 2024 Conference

Chat with this insight

Recent Analyst Ratings for $ZURA

$ZURA SEC Filings

Zura Bio Limited filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-Q filed by Zura Bio Limited

Zura Bio Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$ZURA Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Ploos Van Amstel Arnout bought $496,000 worth of Class A ordinary shares (80,000 units at $6.20), increasing direct ownership by 400% to 100,000 units (SEC Form 4)

Howell Michael bought $24,999 worth of Class A ordinary shares (7,987 units at $3.13) (SEC Form 4)

Nistala Kiran bought $10,000 worth of Class A ordinary shares (3,195 units at $3.13) (SEC Form 4)

$ZURA Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Zura Bio Limited

Amendment: SEC Form SC 13G/A filed by Zura Bio Limited

SEC Form SC 13G filed by Zura Bio Limited

$ZURA Press Releases

Fastest customizable press release news feed in the world

$ZURA Leadership Updates

Live Leadership Updates

$ZURA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis

Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Zura Bio to Participate in Two Upcoming Investor Conferences in November

Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer

Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO

Leerink Partners initiated coverage on Zura Bio Limited with a new price target

H.C. Wainwright initiated coverage on Zura Bio Limited with a new price target

Piper Sandler initiated coverage on Zura Bio Limited with a new price target

$ZURA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Thiara Parvinder sold $10,260,000 worth of Class A Ordinary Shares (3,800,000 units at $2.70) (SEC Form 4)

Amendment: Officer Nistala Kiran was granted 3,195 units of Class A ordinary shares (SEC Form 4)

Director Sidhu Someit sold $200,187 worth of Class A ordinary shares (51,728 units at $3.87), decreasing direct ownership by 2% to 2,085,418 units (SEC Form 4)

$ZURA Financials

Live finance-specific insights

Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Zura Bio Reports Second Quarter 2023 Financial Results and Recent Business Highlights

$ZURA Market Insights

Live Market Insights

Watching Monte Rosa Therapeutics, Zura Bio; Shares See Volume Amid TipRanks Issues Report Mentioning The Two Stocks

Cantor Fitzgerald Reiterates Overweight on Zura Bio

Zura Bio Shares Supportive Data From Phase 1 Study Evaluating Lead Candidate, tibulizumab (ZB-106), For Treatment Of Sjogren's Syndrome

Recent Analyst Ratings for
$ZURA

$ZURA
SEC Filings

$ZURA
Insider Purchases

$ZURA
Large Ownership Changes

$ZURA
Press Releases

$ZURA
Leadership Updates

$ZURA
Analyst Ratings

$ZURA
Insider Trading

$ZURA
Financials

$ZURA
Market Insights